FLT3 and acute myeloid leukemia: Important interventions in AML with MRD in CR may include allogeneic SCT; investigational approaches with more intensified chemotherapy regimens, or with HMAs (parenteral or newly approved oral formulations) plus venetoclax; targeted therapy combinations when indicated for particular molecular abnormalities (FLT3 or IDH inhibitors); antibody therapies (e.g., CD123 or CD33 monoclonal or BiTEs); or immune therapies (e.g., checkpoint inhibitors).